Division of Infectious Disease & International Medicine
College of Medicine - Department of Internal Medicine

Douglas A. Holt, MD, FACP

Professor of Medicine, Division of Infectious Disease & International Medicine
Associate Director, Division of Infectious Disease & International Medicine
Director, Hillsborough County Health Department, Tampa, FL
Biographical Sketch | Areas of Expertise | Current Research | Publications
Education
Residency, Internal Medicine Program, University of South Florida
Fellowship, Infectious Disease, University of South Florida, Tampa, FL
MD, University of South Alabama College of Medicine, Mobile, AL
BS, Davidson College, Davidson, NC
Contact Information
E-Mail: dholt@health.usf.edu
Phone: (813) 307-8008 ext 6301
FAX: (813) 272-6984

Biographical Sketch

Douglas A. Holt, MD, FACP, is Professor of Medicine and Associate Director of the Division of Infectious Disease & International Medicine. He is serves the Director of the Hillsborough County Health Department (HCHD) which is the fourth largest of Florida’s health departments. Dr. Holt earned his medical degree from the University of South Alabama in 1984. He moved to Tampa where he completed his residency in internal medicine at the University of South Florida College of Medicine and his fellowship in infectious disease. He served as the Division’s first Chief Fellow and was also named the “Cuba Geigy Outstanding Resident.” After completing his fellowship, Dr. Holt joined the USF faculty in 1989.
 
Dr. Holt’s energy brought many changes to the Division. He pioneered collaborative work with the burn unit, solid organ transplant, BMT and trauma. He was recognized in 1990 and again in 1991 as “Best Teacher” by the fellows. He guided the fellowship program and helped start the first HIV ward in Florida.
He has been PI or co-PI on 57 research protocols, secured a $1 million HUD grant for a research facility buildout and authored 21 peer-reviewed publications. He is a graduate of the Public Health Leadership Institute Class 1. Prior to being appointed as the Director of the Hillsborough County Health Department he was the Chief of Medical Staff for two years. Dr. Holt was also the Acting Deputy State Health Officer in September of 2001 to February 2002 and helped direct the anthrax investigation in Lantana, Florida. He is an active member of many national, state and local organizations such as the American College of Physicians, Infectious Disease Society of America, Hillsborough County Medical Association, American Medical Association, Public Health Leadership Society, the Florida Medical Association, Florida Infectious Disease Society, Hillsborough Community College Foundation Board of Director’s, National Association of County & City Health Officials. In addition to the community activities, Dr. Holt has played an active role in many Florida Department of Health workgroups and committees, including the Fiscal Management Advisory Council, Fetal Infant Mortality Review Board, the Secretary’s Roundtable, and the Florida Association of County Health Officers.
 
As a Professor and Associate Director, Dr. Holt convenes our public health conference, assists with RRC preparation, and actively attends on infectious disease rounds. He is acclaimed as an outstanding teacher by students, residents and fellows. One of his primary goals has been the integration of public health services and those of the university, a seamless system that would enhance patient care and avoid duplication of service. Through his efforts, the Florida Department of Health and USF have cooperative agreements that provide $600,000 a year to obtain professional medical services from university professors who serve in the critical public health positions of communicable disease and HIV research. He is actively pursuing affiliating the state IRB and the USF IRB.
 
He is most proud of fostering research. During his tenure as Professor and Health Department Director literally hundreds of research studies have been completed and grants submitted. He has been named “Outstanding Teacher in Infectious Disease” and has also been a charter member of the Cardiac Transplant and Liver Transplant Teams at Tampa General Hospital. He is married with two children.  

Areas of Expertise

  • Pandemic Preparedness
  • Public Health Policy
  • Influenza

Current Research

Holt DA. Steps to a Healthier Hillsborough County. Health and Human Services, 2004-09.

Holt DA. A Probe Study to Evaluate the Safety, Tolerability, and Immunogenicity of the MRK Adenovirus Serotype 5 Vector (MRKAd5) Human Immunodeficiency Virus Type I (HIV-1) gag Vaccine in HIV-1 Infected Individuals.  Merck V520 – 014

Holt DA. Early Access of TMC114 in Combination With Low-Dose Ritonavir (RTV) and Other Antiretrovirals (ARVs) in Highly Treatment Experienced HIV-1 Infected Subjects With Limited or No Treatment Options” [TMC114-C226]

Wills T; Holt DA. A Phase III randomized, double-blinded, placebo-controlled trial to investigate the efficacy, tolerability and safety of TMC125 as part of an ART including TMC114/RTV and an investigator-selected OBR in HIV-1 infected subjects with limited to no treatment options. TMC125-C206

Wills T; Holt DA. A Phase 2, Randomized Study of the Treatment of Antiretroviral Treatment-Experienced, HIV-1 Infected Subjects Comparing Ritonavir-Boosted GS-9137 (GS-9137/r) Versus a Comparator Ritonavir-Boosted Protease Inhibitor (CPI/r) in Combination with a Background Antiretroviral Therapy”  [GS-US-183-0105]

Wills T; Holt DA. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of a Novel CCR5 Antagonist, UK-427,857, in Combination with Optimized Background Therapy versus Optimized Background Therapy alone for the Treatment of Antiretroviral-Experienced HIV-1 Infected Subjects. Pfizer A4001027

Somboonwit C; Holt DA. A randomized, controlled, partially blinded Phase IIb dose-finding trial of TMC125, in HIV-1 infected subjects with documented genotypic evidence of resistance to currently available NNRTIs and with at least three primary PI mutations  [Protocol No. TMC125-C223]

Somboonwit C; Holt DA. A Large, Simple Trial Comparing Two Strategies for Management of Anti-Retroviral Therapy. SMART CPCRA 065

Somboonwit C; Holt DA. A Phase II, Randomized, Blinded, 12-Week Comparison of Elvucitabine in Combination with Efavirenz and Tenofovir Versus Lamivudine in Combination with Efavirenz and Tenofovir in HIV-1 Infected, Treatment-Naïve Subjects, with a 12-Week Extension Treatment Period ACH443-015

Somboonwit C; Holt DA. A randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114/ritonavir versus lopinavir/ritonavir in treatment-naïve HIV-1 infected subjects. This trial will be referred to as ARTEMIS. [Protocol No. TMC114-211]

Montero J; Holt DA. A Phase IIb, Randomized, Partially Blinded, Dose-Finding Trial of TMC278 in Antiretroviral Naïve HIV-1 Infected Subjects TMC278-204

Casanas B; Holt DA. An Open-Label Trial with TMC125 in HIV-1 Infected Subjects, Who Were Randomized to a TMC125 Treatment Arm in a Sponsor-Selected TMC125 Trial and were Treated for at least 48 Weeks  TMC125-C229

Casanas B; Holt DA. A 96-Week, Phase IV, Randomized, Double-Blind, Multicenter Study of the Safety and Efficacy of Epzicom Versus Truvada Administered in Combination with Kaletra in Antiretroviral-Naive HIV-1 Infected Subjects” [Protocol No. EPZ104057] –HEAT

Casanas B; Holt DA. A Randomized, Prospective Study of the Efficacy, Safety and Tolerability of Two Doses of GW433908/Ritonavir Given with Abacavir/Lamivudine Fixed Dose Combination. COL100758

Montero J; Holt DA. A Randomized, Controlled, Open-Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV versus LPV/RTV in Treatment-Experienced HIV-1 Infected Subjects. TMC114-C214

Somboonwit C; Holt DA. Vicriviroc in Combination Treatment with an Optimized ART Regimen in HIV-Infected Treatment-Experienced Subjects. Schering Plough – P04889

Wills T; Holt DA. A randomized, open-label trial to compare the efficacy, safety and tolerability of DRV/rtv (800/100 mg) q.d. versus DRV/rtv (600/100 mg) bid in early treatment-experienced HIV-1 infected subjects. Tibotec – TMC114 -C229

Casanas B; Holt DA. A Phase III, randomized, double-blind trial of TMC278 75mg  qd versus efavirenz 600 mg q.d in combination with fixed dose background regimen consisting of tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naïve HIV-1 infected subjects. Tibotec – TMC278 -C209

Montero J; Holt DA. Phase II Randomized, Controlled, Partially Blinded Trial to Investigate Dose Response of TMC114/RTV in 3-Class Experienced HIV-1 Infected Subjects, Followed by an Open-Label Period on the Recommended Dose of TMC114/RTV. Tibotec – TMC114-C202

Casanas B; Holt DA. A Phase 3, Randomized, Open-label Study of Lopinavir/ritonavir Tablets 800/200 mg Once-daily Versus 400/100 mg Twice-daily when Coadministered with Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-experienced, HIV-1 Infected Subjects. Abbott – M06-802

Montero J; Holt DA. Safety and Efficacy of an Initial Regimen of Atazanavir + Ritonavir + the Abacavir/Lamivudine Fixed-Dose Combination Tablet for 36 weeks followed by Simplification to Atazanavir with the Abacavir/Lamivudine Fixed-Dose Combination Tablet or Maintenance of the Initial Regimen for an Additional 48 weeks in Antiretroviral-Naïve HIV-1 Infected HLA-B*5701 Negative Subjects. GlaxoSmithKline – EPZ108859

Casanas B; Holt DA. Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Two-Stage Study to Assess the Efficacy and Safety of Crofelemer 125mg, 250 mg, and  500 mg Orally Twice Daily for the Treatment of HIV-Associated Diarrhea. Napo Pharmaceuticals – NP303-101

Publications

Hauser RA, Furtado S, Cimino CR, Delgado H, Eichler S, Schwartz S, Scott BA, Nauert GM, Soety E, Sossi V, Holt DA, Sanberg PR, Stoessl AJ, Freeman TB: Bilateral human fetal striatal transplantation in Huntington’s disease, Neurology 58: 687-695, 2002.

Ganguly R, Holt DA, Sinnott JT: Exposure of Medical Students to Body Fluids, The Journal of American College Health, 47:207, 1999.

Freeman TB, Olanow CW, Hauser RA, Kordower JH, Holt DA, Borlongan CV, Sanberg PR: Human Fetal Tissue Transplantation, Neurosurgical Treatment of Movement Disorders, The American Association of Neurological Surgeons Chapter 13, 177-192, 1998.

Nadler JP, Oehler RL, Holt DA: Update of Antiretroviral Therapy For HIV Infection, Infections in Medicine 15:113,1998.

Holt DA, Nauert MG, Othberg AI, Randall TS, Willing AE, Widen RH, Hauser RA, Sanberg PR, Olanow CW, Freeman TB: Infectious Issues In Fetal Neural Transplantation, Cell Transplantation, 6:553, 1997.

Holt DA, Larkin JA: Continuing Issues in Ventilator-Associated Pneumonia. Infections in Medicine, 12:12, 1995.

Freeman TB, Olanow CW, Hauser RA, Nauert M, Smith DA, Borlongan CV, Sanberg PR, Holt DA, Kordower JH, Vingerhoets FJG, Snow BJ, Calne D, Gauger BS: Bilateral Fetal Nigral Transplantation into the Postcommissural Putamen in Parkinson's Disease, Annals of Neurology, 38:379, 1995.

Abstracts

Kneer C, Bradley EA, Poblete SA, Sinnott JT, Holt DA, Ganguly: Practice of Universal Precautions Guidelines (UVPG) in Occupational Settings. Infectious Diseases Society of America 36th Annual Meeting, 1998.

Ganguly R, Sinnott JT, Houston SH, Toney JT, Hold DA, Cobian L: Hepatitis B Virus Vaccine: A Measure against occupationally acquired infection. The 35th Annual Meeting of the Infectious Disease Society of America, San Francisco, California, 1997.

Ganguly R, Marty P, Herold A, Desai V, Anderson J, Sinnott JT, Holt DA, Larkin JA, Quiroz E, Callahan C, Mbaga I: Hepatitis B Virus Vaccine Cost: A Barrier to Immunization. The 97th American Society of Microbiology, Miami Beach, Florida, 1997.

Ganguly R, Toney JT, Holt DA, Sinnott JT, Carney M, Cobian L, Desai V: Occupational Risks of Hepatitis B Virus Infection Among Older Health Care Providers (HCP). 1997 Research Day, Office of Research and Graduate Affairs News, University of South Florida College of Medicine, Tampa, Florida, 1997.

Ganguly R, Marty P, Herold A, Desai V, Anderson M, Sinnott JT, Holt DA, Larkin JA, Quiroz E, Callahan C, Mbaga I: Hepatitis B Virus Vaccine Cost: A Barrier to Immunization. The 97th American Society for Microbiology, Miami Beach, Florida, 1997.

Larkin JA, Houston SH, Holt DA, Sinnott JT, Oehler R, Alexander LA: Reduction in Contaminated Allograft Bone Cultures by a Tissue Handling Protocol. The Southern Section, American Federation for Medical Research, New Orleans, Louisiana, 1997.